Group 1 - The high-pressure oxygen chamber concept increased by 2.20%, ranking fourth among concept sectors, with eight stocks rising, including Jinling Pharmaceutical, BeiYikang, and Innovation Medical, which rose by 6.35%, 5.73%, and 3.79% respectively [1] - The main capital inflow for the high-pressure oxygen chamber concept was 0.29 billion yuan, with five stocks receiving net inflows, led by Innovation Medical with a net inflow of 52.09 million yuan [2][3] - The net inflow ratios for International Medical, Innovation Medical, and Jinling Pharmaceutical were 9.48%, 5.21%, and 3.12% respectively, indicating strong investor interest in these stocks [3] Group 2 - The top gainers in the high-pressure oxygen chamber concept included Innovation Medical, International Medical, and Jinling Pharmaceutical, while the top losers were Samsung Medical and Hangyang Co., which fell by 3.20% and 1.14% respectively [1][4] - The trading volume for Innovation Medical was 11.31%, indicating a high turnover rate, while other stocks like International Medical and Jinling Pharmaceutical had lower turnover rates of 1.77% and 4.54% respectively [3]

Core Viewpoint - International Medicine (000516) has experienced a decline in both revenue and net profit for the first three quarters of 2025, indicating potential challenges in its business performance [2]. Financial Performance - For the first three quarters of 2025, the company's main revenue was 2.995 billion yuan, a year-on-year decrease of 16.94% [2]. - The net profit attributable to shareholders was -294 million yuan, down 38.45% year-on-year [2]. - The net profit after deducting non-recurring items was -312 million yuan, a decline of 41.94% year-on-year [2]. - In Q3 2025, the company's single-quarter main revenue was 961 million yuan, a year-on-year decrease of 18.95% [2]. - The single-quarter net profit attributable to shareholders was -129 million yuan, a significant drop of 234.24% year-on-year [2]. - The single-quarter net profit after deducting non-recurring items was -123 million yuan, down 52.03% year-on-year [2]. - The company's debt ratio stood at 68.8%, with investment income of 20.7586 million yuan and financial expenses of 111 million yuan [2]. - The gross profit margin was 6.59% [2]. Market Activity - As of December 16, 2025, the stock closed at 4.5 yuan, down 1.1%, with a turnover rate of 0.52% [1]. - The trading volume was 113,800 hands, with a transaction amount of 51.2548 million yuan [1]. - On December 16, the net outflow of main funds was 4.082 million yuan, accounting for 7.96% of the total transaction amount [1]. - The net outflow of speculative funds was 1.8504 million yuan, representing 3.61% of the total transaction amount [1]. - Retail investors had a net inflow of 5.9323 million yuan, making up 11.57% of the total transaction amount [1]. Analyst Ratings - In the last 90 days, two institutions have given ratings for the stock, both recommending an increase in holdings [3]. - The average target price set by institutions in the past 90 days is 5.5 yuan [3].

证券代码：000516 证券简称：国际医学 公告编号：2025-057 西安国际医学投资股份有限公司 关于召开2025年第二次临时股东会的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 本公司于 2025 年 12 月 4 日在《证券时报》《中国证券报》《上海证券报》 《证券日报》和巨潮资讯网上发布了《关于召开 2025 年第二次临时股东会的通 知》，定于 2025 年 12 月 19 日召开 2025 年第二次临时股东会。为进一步保护 投资者的合法权益，方便本公司股东行使股东会表决权，现根据相关规定，发 布关于召开公司 2025 年第二次临时股东会的提示性公告如下： 一、召开会议的基本情况 1、股东会届次：2025 年第二次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易 所股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上 市公司规范运作》等法律、行政法规、部门规章、规范性文件及《公司章程》 的有关规定。 5、会议的召开方式：现场表决与网络投票相结合。 6、会议的股权 ...

Core Insights - Jinan International Medical Center is transforming into a national-level health industry hub, leveraging policy benefits, financial support, and high-end medical resources to establish a "high-end, specialized, and international" development pattern by 2025 [1][3][10] Medical Services - The Shandong Proton Center within the medical center has treated nearly 2,000 patients, ranking first in the 2024-2025 China Proton and Heavy Ion Center rankings, showcasing advancements in precision radiation therapy [2] Technological Innovation - The medical center is actively participating in major medical technology exhibitions, introducing innovative technologies such as Hi-tACS for treating neuropsychiatric disorders and AI-assisted diagnostic systems, enhancing the development of precision medicine [4][5] Health Industry Development - The Jinan government is supporting the establishment of a national medical center and accelerating the development of medical parks, ensuring efficient招商 (investment attraction) processes through comprehensive management strategies [6][7] International Cooperation - The medical center is expanding its international collaboration by signing agreements with institutions in South Korea, focusing on various medical fields, and hosting annual Sino-Korean health industry cooperation conferences [8] Resource Support - The Shandong government has introduced tailored policies to support the medical center, including financial backing through various funds, facilitating the approval of medical devices, and enhancing project execution efficiency [9][10]

Core Points - The Shenzhen-Hong Kong Stock Connect Medical Index (983036) closed at 4327.65 points, down 0.28%, with a trading volume of HKD 7.682 billion and a turnover rate of 0.9% [1] - Among the index constituents, 21 stocks rose while 36 stocks fell, with Kewei Medical leading the gainers at a 4.14% increase and Xianjian Technology leading the decliners at a 9.14% decrease [1] Index Constituents Summary - The top ten constituents of the Shenzhen-Hong Kong Stock Connect Medical Index include: - Mindray Medical (sz300760) with a weight of 14.56%, latest price at HKD 198.00, and a market cap of HKD 240.063 billion, down 0.36% [1] - Yier Eye Hospital (sz300015) with a weight of 11.62%, latest price at HKD 11.23, and a market cap of HKD 104.724 billion, down 0.62% [1] - Lejin Medical (sz300003) with a weight of 4.85%, latest price at HKD 15.64, and a market cap of HKD 28.831 billion, down 0.64% [1] - Aimeike (sz300896) with a weight of 4.80%, latest price at HKD 143.25, and a market cap of HKD 43.346 billion, up 1.47% [1] - Yuyue Medical (sz002223) with a weight of 4.66%, latest price at HKD 35.68, and a market cap of HKD 35.768 billion, up 0.17% [1] - Yingke Medical (sz300677) with a weight of 3.64%, latest price at HKD 41.76, and a market cap of HKD 27.360 billion, down 0.17% [1] - Furuijia (sz300049) with a weight of 3.59%, latest price at HKD 69.33, and a market cap of HKD 18.371 billion, down 0.82% [1] - Meinian Health (sz002044) with a weight of 3.58%, latest price at HKD 5.09, and a market cap of HKD 19.924 billion, up 0.39% [1] - Sinopharm Holdings (hk01099) with a weight of 3.35%, latest price at HKD 18.15, and a market cap of HKD 56.638 billion, down 0.40% [1] - Ping An Good Doctor (hk01833) with a weight of 2.63%, latest price at HKD 12.23, and a market cap of HKD 26.434 billion, down 3.24% [1] Capital Flow Analysis - The index constituents experienced a net outflow of HKD 382 million from institutional investors, while retail investors saw a net inflow of HKD 329 million [1] - Notable individual stock capital flows include: - Meinian Health (sz002044) with a net inflow of HKD 23.6308 million from institutional investors [2] - Aimeike (sz300896) with a net inflow of HKD 5.8353 million from institutional investors [2] - Yier Eye Hospital (sz300015) with a net outflow of HKD 20.7620 million from retail investors [2]

Core Viewpoint - The company emphasizes the importance of provincial-level coordination in basic medical insurance as a significant step towards improving the national healthcare system, enhancing the efficiency of fund utilization, and meeting diverse medical needs of the public [2] Group 1: Company Developments - The company has developed multiple specialized departments including neurology, cardiology, gastroenterology, thoracic medicine, oncology, hematology, orthopedics, and has undertaken complex medical projects with high technical content [2] - The proportion of out-of-town patients at the company's medical institutions has increased from less than 10% at the start of operations to 42% by the third quarter of 2025 [2] - The company is establishing a comprehensive medical service network based in Xi'an, covering Shaanxi and radiating to the central and western regions of China [2] Group 2: Industry Trends - The company is actively adjusting its business structure to enhance service value, expanding into aesthetic medicine, rehabilitation, women's and children's health, health management, traditional Chinese medicine, assisted reproduction, mental health, special services, elderly care, and proton therapy [2] - This strategic expansion aims to meet the growing and diverse health needs of the public [2]

证券日报网讯 12月10日，国际医学在互动平台回答投资者提问时表示，国际医学作为一个已上市的公 众公司，严格遵循上市公司治理准则与相关法律法规，所有高级管理人员的聘任均履行了合法、合规的 决策程序，其任职资格、专业背景与经验经历符合公司经营管理与发展需要。公司采用"集团化管理， 分院区经营"的模式，在上市公司层面，根据业务发展需要，聘任了具有丰富管理经验、财务经验等专 业背景的高级管理人员，他们为公司规范运作和高效管理提供了有力支持。公司下属医疗机构院级领导 班子成员为医疗专业管理人员，并有深厚的行业管理经验。 （文章来源：证券日报） ...

Group 1 - International Medical aims to create a dual-driven development model of "comprehensive medical care + specialized departments" and has announced a plan to raise up to 1.008 billion yuan through a targeted stock issuance [1] - The raised funds will primarily be invested in smart health care projects, the second phase of the proton therapy center, and to supplement working capital [1] Group 2 - The aging population in China is increasing, with approximately 220 million people aged 65 and above expected by the end of 2024, representing 15.6% of the total population [2] - China's total healthcare expenditure has grown from 3.54 trillion yuan in 2014 to 9.06 trillion yuan in 2023, with a compound annual growth rate of 11.01% [2] - The demand for healthcare services is expected to rise due to the increasing elderly population and enhanced health awareness among residents [2] Group 3 - The proportion of nursing beds in registered elderly care institutions in China was 65.7% by the end of 2024, indicating significant growth potential in the elderly care industry [3] - Policies have been introduced to promote the integration of medical and elderly care services, aiming to improve the care system for elderly individuals with disabilities or dementia [3] Group 4 - Proton therapy is highlighted as a cutting-edge cancer treatment method with high cure rates and low side effects, addressing the limitations of traditional radiation therapy [4] - There is a significant market demand for proton therapy in China, with only seven operational proton therapy centers as of 2024, despite approximately 4.8247 million new cancer cases reported in 2022 [4] Group 5 - The health policy framework aims to enhance cancer prevention and treatment systems by 2030, with a planned increase in the number of radiation therapy devices [5] - The proton therapy center's second phase project aligns with national industrial policy and aims to enhance the company's high-end diagnostic capabilities [6] Group 6 - The implementation of the fundraising projects will enable the company to extend its business from traditional diagnostics to high-end radiation therapy, creating a synergistic business model of "comprehensive diagnosis + precise radiation therapy" [6] - The projects will leverage existing medical resources to strengthen the company's core competitiveness in cancer treatment [6]

12月4日，国际医学公告称，公司拟定增募资不超10.08亿元。国际医学表示，公司本次募集资金将重点 投向智慧康养项目，该项目将使用公司旗下闲置场地开展，盘活存量资产。此外，国际医学还拟将部分 募集资金投入质子治疗中心二期项目，旨在打造、完善西北地区头一家投用的质子治疗项目，紧抓市场 机遇，带动中西部地区肿瘤治疗水平提升。 12月3日，佐力药业公告称，拟发行可转债募资不超15.56亿元。投向智能化中药大健康工厂(一期)、"乌 灵+X"产品研发项目以及补充流动资金。据悉，自2011年上市以来，公司累计已完成三次股权融资，募 资金额为18.66亿元。截至目前，公司累计分红金额达14.42亿元，分红率达57.96%。 12月以来，医药企业融资密集。值得注意的是，截至目前，已有至少5家医药上市公司启动再融资，涵 盖港股配售、A 股定增、可转债发行和资产证券化四大模式。 近日，三生制药公告称拟以每股29.62港元配售价配售1.051695亿股、占其发行后股份总数约4.14%，配 股融资总额约31.1512亿港元，融资净额30.8684亿港元。所得资金将用于全球及中国研发、基础设施建 设、设施购置及一般用途。摩根士丹利担任 ...

Core Viewpoint - International Medical (000516.SZ) is initiating a new round of capital operations to address ongoing losses and liquidity pressures by planning a private placement of A-shares to raise up to 1.008 billion yuan [1][2][3]. Fundraising Purpose - The capital raised will primarily be allocated to three projects: approximately 638 million yuan for a smart healthcare project, about 100 million yuan for the second phase of a proton therapy center, and 270 million yuan to supplement working capital [4][5]. Financial Challenges - The company has faced a high asset-liability ratio and has reported continuous losses for seven years, with a cumulative loss of 2.621 billion yuan from 2021 to 2024. In the first three quarters of 2025, revenue decreased by 16.94%, while losses increased by 38.45% [2][7]. Capital Allocation Strategy - The allocation of funds reflects the company's attempt to balance long-term strategic investments with short-term liquidity needs. The proton therapy center is capital-intensive with a long payback period, while the smart healthcare project also requires significant upfront investment [6]. Liquidity Improvement - The 270 million yuan earmarked for working capital is crucial for meeting daily operational needs and reducing reliance on debt financing, thereby alleviating interest burdens [8]. Shareholder Concerns - The frequent and high proportion of share pledges by the controlling shareholder, Century Xinyuan, raises concerns about the company's governance and financial stability. As of May 2025, 70.10% of the shares held by the controlling shareholder were pledged, increasing to 81.45% by June [9][10]. Market Reaction - The stock price of International Medical has been on a downward trend, reaching 4.7 yuan per share as of December 4, with a total market capitalization of 10.52 billion yuan. The risks associated with share pledges and the company's financial situation are significant factors for investors [11].